Chronic primary vasculitis describes a group of rare, life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain.
The challenge in treating children with vasculitis is balancing the risk of under treating aggressive disease with the potential damaging side-effects of prolonged use of drugs.
This project uses an established international web-based registry to collect clinical information from 50 or more centers worldwide, with approximately 20 centres contributing paired biological samples (DNA, RNA, plasma, serum, urine). The goal is to elucidate subclinical (molecular/cellular) features which help to classify, define and direct optimal treatment for children with vasculitis.
The Pediatric Vasculitis Initiative (PedVas)
The PedVas study is an international study, headed by Dr. David Cabral, based at BC Children’s Hospital and includes collaborators in Canada, US, and various countries across the globe. The project is funded by the Canadian Institutes of Health Research (CIHR). This study is examining childhood chronic vasculitis, a set of inflammatory diseases affecting blood vessels in body organs such as the kidneys, lungs and brain.
Identification of novel ADA2/CECR1 gene variants and varied clinical phenotype in pediatric vasculitis
Sterile inflammatory activation of human coronary artery endothelial cells induced by S100A12 is driven by monocyte-derived interleukin 1β
S100A12 and common inflammatory markers improve assessment of disease activity in a PedVas cohort of childhood systemic vasculitis
Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey